STOCK TITAN

G Form 144: 25,539 Common Shares to Be Sold on NYSE via Morgan Stanley

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 notice for Genpact Limited (symbol: G) discloses a proposed sale of 25,539 common shares through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $1,164,468.47 and approximately 174,270,076 shares outstanding. The shares were acquired as performance shares: 17,608 on 01/10/2022 and 7,931 on 01/10/2023. No securities were reported sold by the selling person in the past three months. The filer certifies they are unaware of any undisclosed material adverse information and follows the Rule 144 disclosure process.

Positive

  • Clear disclosure of planned sale details including broker, sale date, share count, and aggregate market value
  • Securities were awarded as performance shares with acquisition dates provided, supporting transparency
  • No reported sales in the prior three months, indicating this is not part of an ongoing rapid disposition

Negative

  • None.

Insights

TL;DR: Routine Rule 144 filing disclosing an insider's planned sale of performance shares worth ~$1.16M; appears compliant and non-material.

The filing documents a standard Rule 144 notice: a sale of 25,539 common shares via Morgan Stanley Smith Barney on NYSE with an aggregate value of $1,164,468.47. The shares were awarded as performance shares in 2022 and 2023, which the filer discloses clearly. There are no sales in the prior three months, and the signature statement affirms no undisclosed material adverse information. From a compliance standpoint, the form supplies required acquisition dates, share counts, broker details, and planned sale date, supporting orderly, rule-based disposition of restricted or controlled shares.

TL;DR: The disclosed sale size (~$1.16M) is small relative to a large-cap issuer and unlikely to be market-moving.

The notice shows an insider intends to sell 25,539 common shares valued at about $1.16 million against ~174.27 million shares outstanding. Given those totals, the transaction represents a small fraction of outstanding equity and lacks other red flags such as recent accelerated sales. The classification of the shares as performance shares and the absence of recent sales suggest routine vesting and monetization rather than a liquidity-driven exit. Impact on the stock from this single filing is likely neutral.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Genpact (G) Form 144 disclose?

The notice discloses a proposed sale of 25,539 common shares valued at $1,164,468.47 to be executed on 08/22/2025 via Morgan Stanley Smith Barney LLC on the NYSE.

How were the shares to be sold by the filer acquired?

The shares were acquired as performance shares: 17,608 on 01/10/2022 and 7,931 on 01/10/2023.

Has the filer sold other Genpact shares in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Which broker and exchange are involved in the proposed sale?

The broker is Morgan Stanley Smith Barney LLC, and the sale is to occur on the NYSE.

What does the filer certify regarding material information?

By signing, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Genpact Limited

NYSE:G

G Rankings

G Latest News

G Latest SEC Filings

G Stock Data

8.29B
158.11M
0.87%
104.38%
3.99%
Information Technology Services
Services-management Consulting Services
Link
Bermuda
HAMILTON